Telix Pharmaceuticals Limited Announces Unaudited Revenue Results for the Fourth Quarter and Full Fiscal Year 2023
The total revenue (unaudited) for Fiscal Year 2023 is $502.5 million (USD 333.0 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20 AUD | +0.35% |
|
+13.96% | +98.41% |
1st Jan change | Capi. | |
---|---|---|
+98.41% | 4.48B | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |